Copenhagen, Denmark - 14 December, 2010 - Topotarget A/S (NASDAQ-OMX: TOPO.CO) announced today that it has appointed Annette Lykke as new Director of Investor and Public Relations. The goal is to ensure a high level of communication between the Company and it's institutional investors and to step up the relations with Topotarget's private shareholders.

Copenhagen, 14 December, 2010, 2010-12-14 16:39 CET (GLOBE NEWSWIRE) -- Annette Lykke joins Topotarget as new Director of Investor and Public Relations
on 3 January, 2011. Annette holds a M.Sc. in Economics (cand.polit.) from the
Copenhagen University, Denmark, and has a background as senior pharma and
biotech analyst with several leading Nordic investment banks, including
Carnegie, ABN AMRO Alfred Berg and Unibørs (now Nordea Markets). Annette has on
previous occasions been rated number one pharma and biotech analyst among
Danish investment banks.

"I am delighted that Annette Lykke has decided to join Topotarget as new
Director of Investor and Public Relations. Annette has a tremendous knowledge
and experience within both the biotech industry and the equity markets. Hence,
she will be a key person in ensuring our relations to our current and potential
institutional investors as well as in our wish to increase our efforts and
relations to Nordic private shareholders", said Anders Vadsholt, CFO of
Topotarget.

Topotarget expects to host private shareholder events in both Copenhagen and
Stockholm in the beginning of 2011. Time and venue for these events will be
announced on Topotarget's website in due course.

Topotarget A/S

For further information please contact

Francois Martelet, CEO: Direct: +45 39 17 83 43; Mobile: +45 51 32 83 41
Anders Vadsholt, CFO: Direct: +45 39 17 83 45; Mobile: +45 28 98 90 55

Background information

About Topotarget

Topotarget (NASDAQ OMX: TOPO) is a Scandinavian based international biotech
company headquartered in Denmark, dedicated to improve cancer therapies. In
collaboration with Spectrum Pharmaceuticals, Inc. Topotarget currently focuses
on the development in pivotal studies of its lead drug candidate, belinostat,
which has demonstrated a clear anti neoplastic effect in both hematological
malignancies and solid tumors. Belinostat can be used in combination with full
doses of chemotherapy, and is currently in a pivotal trial within PTCL
(peripheral T-cell lymphoma) and phase II in cancer of unknown primary (CUP).
Topotarget's key cancer drug targets are HDAC, NAD+, mTOR, Fas ligand and
topoisomerase II. Totect(R)is a product on the market developed from
Topotarget's drug discovery technology. Totect(R)is marketed by the company's
own sales specialists in the US. The European rights to Savene(R)were divested
in March 2010 as a consequence of the focus to develop and commercialise
belinostat. For more information, please refer to www.topotarget.com.

Topotarget Safe Harbour Statement

This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline including the timing for commencement and completion of clinical
trials and with respect to cash burn guidance. Such statements are based on
management's current expectations and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements. Topotarget cautions investors that
there can be no assurance that actual results or business conditions will not
differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: The risk that any one or more of the drug development programs of
Topotarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
non-clinical or clinical studies or from other sources; the success of
competing products and technologies; technological uncertainty and product
development risks; uncertainty of additional funding; Topotarget's history of
incurring losses and the uncertainty of achieving profitability; Topotarget's
stage of development as a biopharmaceutical company; government regulation;
patent infringement claims against Topotarget's products, processes and
technologies; the ability to protect Topotarget's patents and proprietary
rights; uncertainties relating to commercialization rights; and product
liability exposure; We disclaim any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.

Investor News No 07-10 Topotarget appoints Annette Lykke as new Director of Investor and Public Relations.pdf